— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected.
— Revenue grew 85% to $143.3 million, versus $136.01 million expected. Net product revenue increased 84% year-over-year to $142 million, driven mainly by an increase in total Vascepa prescriptions in the US.
— For full-year 2020, Amarin expects revenues to be $650 million to $700 million.
— AMRN shares gained 2% during the aftermarket hours.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
